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Abstract
Objective: Metabolic syndrome and obesity are risk factors for chronic kidney disease. 
However, early kidney alterations may escape diagnosis in these conditions due to 
glomerular hyperfiltration. Uromodulin, a glycoprotein exclusively synthesized in tubular 
cells of the thick ascending limb of Henle´s loop, is a novel tissue-specific biomarker for 
kidney function. In contrast to the commonly used markers creatinine and cystatin C, 
serum uromodulin does not primarily depend on glomerular filtration. We hypothesized 
that serum uromodulin is a marker for metabolic syndrome and related components.
Design: The analyses included 1088 participants of the population-based KORA F4 
study aged 62–81 years. Metabolic syndrome was present in 554 participants. After a 
mean follow-up time of 6.5 years, 621 participants were reevaluated, of which 92 had 
developed incident metabolic syndrome.
Methods: The association of serum uromodulin with metabolic syndrome and its 
components were assessed using multivariable logistic regression models.
Results: Serum uromodulin was inversely associated with metabolic syndrome after 
adjustment for sex, age, estimated glomerular filtration rate, physical activity, smoking, 
alcohol consumption and high-sensitivity C-reactive protein (OR 0.65; 95% CI 0.56–0.76 
per standard deviation uromodulin; P < 0.001). Serum uromodulin was inversely 
associated with all single components of metabolic syndrome. However, serum 
uromodulin was not associated with new-onset metabolic syndrome after the follow-up 
period of 6.5 ± 0.3 years (OR 1.18; 95% CI 0.86–1.60).
Conclusions: Serum uromodulin is independently associated with prevalent, but not with 
incident metabolic syndrome. Low serum uromodulin may indicate a decreased renal 
reserve in the metabolic syndrome.
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The metabolic syndrome is associated with an increased 
risk for cardiovascular and renal complications, and 
chronic renal failure in metabolic syndrome may 
progress to end-stage renal disease (1, 2). Kidney 
pathophysiological alterations reveal a type of ischemic 
nephropathy with predominant tubular atrophy in 
addition to interstitial fibrosis, microvascular sclerosis 
and segmental glomerulosclerosis (3, 4). However, kidney 
alterations in metabolic syndrome may escape early 
clinical diagnosis, since obesity and other components of 
the metabolic syndrome, such as elevated fasting glucose 
and elevated blood pressure, are associated with glomerular 
hyperfiltration. The currently available kidney function 
markers (creatinine, cystatin C and urea) all reflect the 
glomerular filtration rate (GFR) and may thus deliver falsely 
inconspicuous results in case of glomerular hyperfiltration. 
Additionally, obesity may be associated with variable 
degrees of skeletal muscle loss, including sarcopenic 
obesity, which is especially frequent in elderly individuals 
and can further influence the estimated GFR (eGFR) values 
based on creatinine (5). Therefore, additional kidney 
function markers not directly depending on glomerular 
filtration would be useful to unravel early kidney disease 
in elderly individuals with metabolic syndrome.
The currently most promising alternate marker of 
kidney function is uromodulin. Uromodulin is a tissue-
specific glycoprotein synthesized in tubular cells of the 
thick ascending limb of Henle´s loop. The larger proportion 
of uromodulin is secreted into the urinary tract, where 
it is the most abundant protein under physiological 
conditions (50–100 mg/24 h) and exerts anti-infective, 
anti-lithogen and immunomodulatory functions (6, 7, 8, 
9, 10). In addition to the apical secretion, a small amount 
of uromodulin is secreted basolaterally into the interstitial 
space and transferred into the blood stream (11, 12, 
13). The physiological function of serum uromodulin 
(sUmod) is elusive to date, but sUmod emerged as a 
highly interesting marker of kidney function (12, 13). As 
a tubular protein, sUmod does not directly depend on 
glomerular filtration, but mirrors tubular integrity and 
indirectly nephron mass and thus the renal reserve (14).
In the current study, we used sUmod as a novel 
marker of kidney integrity in elderly participants of the 
population-based KORA F4 cohort. We hypothesized that 
sUmod was inversely associated with metabolic syndrome 
independently of the eGFR, indicating a decreased renal 




The KORA (Cooperative Health Research in the Region 
of Augsburg) F4 (2006-2008) and FF4 (2013-2014) cohort 
studies are follow-up examinations of the population-
based KORA S4 study (1999-2001). Recruitment and 
eligibility criteria for the KORA studies have been 
described previously (15). The study design, standardized 
sampling methods and data collection (medical history, 
medication, anthropometric measurements, blood 
pressure) have been described in detail elsewhere (16, 
17). All study participants gave written informed consent. 
The study was approved by the Ethics Committees of 
the Bavarian Medical Association in adherence to the 
Declaration of Helsinki. sUmod was measured in the 
1119 participants aged 62–81 years of the KORA F4 
study with available serum samples (from a total of 1161 
participants in this age group). All variables necessary 
for the cross-sectional analyses were available in 1088 
participants. Of these 1088 participants, 116 died and 
341 declined participation in the FF4 survey or could not 
be contacted. Thus, the study sample in the longitudinal 
F4/FF4 examination comprised 631 participants, of which 
ten were excluded due to missing covariables, leaving 621 
participants for the longitudinal analyses (Supplementary 
Fig. 1, see section on supplementary data given at the end 
of this article). The follow-up time was 6.5 ± 0.3 years. 
Clinical characteristics of the participants included in 
the follow-up analysis are available in Supplementary 
Table 1. Metabolic syndrome was defined according 
to the International Diabetes Federation definition as 
presence of at least three of the following five criteria: (1) 
elevated waist circumference (waist circumference ≥94 cm 
in men and ≥80 cm in women); (2) fasting triglycerides 
≥1.7 mmol/L and/or use of fibrates or nicotinic acid; 
(3) high-density lipoprotein (HDL) cholesterol <1.0 mmol/L 
in men or <1.3 mmol/L in women and/or use of fibrates 
or nicotinic acid; (4) fasting glucose ≥5.6 mmol/l and/or 
use of glucose-lowering medication; (5) elevated blood 
pressure (systolic blood pressure ≥130 mmHg and/or 
diastolic blood pressure ≥85 mmHg and/or use of 
antihypertensive medication, given that the participants 
were aware of being hypertensive) (18). No participant 
took omega 3 fatty acid in a dose ≥2 g/day. Leisure time 
physical activity was assessed with two separate questions 
concerning leisure time sport activity in winter and in 
summer (cycling included). Possible answers were (1) >2 h, 
(2) 1–2 h, (3) <1 h and (4) none per week. Participants who 
had a total score <5, obtained by summing the numbers 
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(1)–(4) relating to winter and summer, were classified to be 
‘physically active’. Alcohol consumption was categorized 
in three groups defined as no (0 g/day), moderate 
(men 0.1–39.9 g/day and women 0.1–19.9 g/day), 
and high (men ≥40 g/day and women ≥20 g/day) 
alcohol consumption. Smoking behavior was categorized 
into three groups (active smoker, former smoker, 
never smoker).
Laboratory measurements
Blood was collected after an overnight fast of at least 
8 h. The samples were kept at room temperature until 
centrifugation. Plasma and serum samples were assayed 
immediately or stored at −80°C. Measurements of serum 
creatinine (fresh serum), high-sensitivity C-reactive 
protein (hsCRP) (frozen plasma), glucose (fresh serum), 
total cholesterol, low-density lipoprotein (LDL), HDL 
and triglycerides (all fresh serum) were performed as 
described previously (19, 20). sUmod (frozen serum) was 
measured with a commercially available enzyme-linked 
immunosorbent assay kit (Euroimmun AG, Lübeck, 
Germany) with a lower detection limit of 2 ng/mL, an 
intra-assay coefficient of variation of 2.3% and inter-assay 
coefficients of variation of 4.4% and 9.5% for sUmod 
target values of 24.9 and 142.2 ng/mL, respectively. The 
measurement procedure was performed as described by 
Steubl et  al. (12). Estimated glomerular filtration rate 
(eGFR) was calculated using the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation (2009) 
based on serum creatinine (21).
Statistical analyses
Characteristics of the study participants were compared 
between participants with and without metabolic 
syndrome using t-tests in case of approximately 
normally distributed variables. Mann–Whitney U tests 
were performed for variables with skewed distributions. 
Binomial proportions were compared with chi-square 
tests. The associations of sUmod with the outcomes of 
interest were assessed in logistic regression models in case 
of categorical dependent variables and in linear regression 
models in case of continuous dependent variables. sUmod 
was analyzed as log-transformed continuous independent 
variable per standard deviation. In multinomial logistic 
and linear regression analyses, the associations of sUmod 
with the respective dependent variables were adjusted for 
covariates in different models: Model 1: age (continuous) 
and sex; Model 2: Model 1 plus eGFR (log-transformed, 
continuous); Model 3: Model 2 plus physical activity 
(active/inactive), smoking status (never/former/current), 
and alcohol consumption (no/moderate/high); Model 
4: Model 3 plus hsCRP (log-transformed, continuous); 
Model 5: Model 4 plus arterial hypertension (yes/no) 
and fasting glucose (continuous); Model 6: Model 5 
plus BMI (continuous) and treatment with statins and 
fibrates (yes/no, respectively). Model 1 and Model 2 were 
calculated for all outcome variables; Model 3 and Model 
4 for the metabolic syndrome and its components; Model 
5 for anthropometric measures and Model 6 for lipid 
parameters as outcome variables. Preexisting cases were 
excluded from the longitudinal incidence analyses. The 
level of statistical significance was set at 5% (two-sided). 
All calculations were performed using the statistical 
environment R, version 3.5.2.
Results
Study population characteristics
Table 1 displays the baseline characteristics of the total 
study population and stratified by metabolic syndrome. 
Metabolic syndrome was present in 43% of the participating 
women and in 56% of the men, corresponding to 51% of 
the total cohort. Participants with metabolic syndrome 
had significantly lower sUmod concentrations compared 
to participants without metabolic syndrome (P < 0.001).
Inverse association of sUmod with the 
metabolic syndrome
sUmod displayed an inverse association with the metabolic 
syndrome (odds ratio (OR) 0.58; 95% confidence interval 
(CI) 0.50–0.67) after adjustment for sex and age (Table 2). 
Additional correction for eGFR modestly attenuated 
the association (OR 0.61; 95% CI 0.53–0.70). Further 
adjustment for physical activity, smoking and alcohol 
consumption had hardly any influence (OR 0.62; 95% CI 
0.53–0.72) and additional adjustment for hsCRP did not 
substantially attenuate the associations of sUmod with 
the metabolic syndrome (OR 0.65; 95% CI 0.56–0.76).
Inverse association of sUmod with single 
components of the metabolic syndrome
sUmod was inversely associated with each single 
component of the metabolic syndrome (Table 2). 
After adjustment for age, sex, eGFR, physical activity, 
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smoking and alcohol consumption, sUmod was 
significantly inversely associated with an elevated waist 
circumference, elevated triglycerides, reduced HDL 
cholesterol, elevated fasting glucose and elevated blood 
pressure. As for the metabolic syndrome itself, the major 
influencing factor for the associations of sUmod with 
the single metabolic syndrome components was eGFR, 
except for the association of sUmod with elevated waist 
circumference, which was hardly influenced by adjustment 
for eGFR. Additional adjustment for hsCRP attenuated 
most of the associations of sUmod with the metabolic 
syndrome and its components moderately, which still 
remained significant, except for the association of sUmod 
with elevated waist circumference that lost significance.
Table 1 Characteristics of the study participants.a
Total study cohort No metabolic syndrome Metabolic syndrome P value
n 1088 534 554
Female sex, n (%) 537 (49) 301 (56) 236 (43) <0.001k
Age (years) 70.3 ± 5.5 70.1 ± 5.6 70.5 ± 5.4 0.32i
Elevated waist circumference n (%)b 913 (84) 375 (70) 538 (97) <0.001k
Elevated triglycerides n (%)c 308 (28) 31 (6) 277 (50) <0.001k
Reduced HDL cholesterol n (%)d 206 (19) 17 (3) 189 (34) <0.001k
Elevated fasting glucose n (%)e 528 (49) 80 (15) 448 (81) <0.001k
Elevated blood pressure n (%)f 797 (73) 288 (54) 509 (92) <0.001k
BMI (kg/m2) 28.7 ± 4.3 26.9 ± 3.9 30.4 ± 4.3 <0.001i
Waist circumference (cm) 98.1 ± 12.1 92.5 ± 10.9 103.4 ± 10.6 <0.001i
Waist-to-hip ratio 0.91 ± 0.08 0.88 ± 0.08 0.94 ± 0.07 <0.001i
Total cholesterol (mmo/L) 5.77 ± 1.04 5.85 ± 1.04 5.69 ± 1.07 0.007i
HDL cholesterol (mmol/L) 1.45 ± 0.37 1.61 ± 0.34 1.30 ± 0.31 <0.001i
Ratio total cholesterol/HDL cholesterol 4.18 ± 1.13 3.75 ± 0.87 4.59 ± 1.19 <0.001i
LDL cholesterol (mmol/L) 3.65 ± 0.93 3.67 ± 0.94 3.61 ± 0.93 0.24i
Triglycerides (mmol/L) 1.28 (0.93; 1.78) 1.06 (0.82; 1.35) 1.70 (1.20; 2.33) <0.001j
hsCRP (mg/dL) 1.52 (0.78; 3.11) 1.29 (0.64; 2.48) 1.98 (0.98; 3.82) <0.001j
eGFR (mL/min/1.73 m2) 77.9 (67.3; 87.7) 80.1 (67.3; 87.8) 75.4 (64.2; 86.2) <0.001j
Physically inactive n (%)g 537 (49) 236 (44) 301 (54) 0.001k
Smoker never/former/current (%) 49/45/6 51/41/7 47/48/5 0.07k
Alcohol consumption no/moderate/high (%)h 32/56/12 30/59/11 33/54/13 0.23k
Serum uromodulin (ng/mL) 153 (111; 208) 176 (130; 227) 132 (99; 186) <0.001j
aMean ± standard deviation, median (first quartile; third quartile), or number of participants (proportion in %). bDefined as ≥80 cm in women and ≥94 cm 
in men. cDefined as ≥1.7 mmol/L and/or intake of fibrates or nicotinic acid. dDefined as <1.0 mmol/L in men and <1.3 mmol/L in women and/or intake of 
fibrates or nicotinic acid. eDefined as ≥5.6 mmol/L and/or intake of anti-diabetic medication. fDefined as systolic blood pressure ≥130 mmHg and/or 
diastolic blood pressure ≥85 mmHg and/or use of antihypertensive medication, given that the participants were aware of being hypertensive. gPhysically 
inactive: <1-h sports/week in winter and summer. hAlcohol consumption: no (0 g/day), moderate (men 0.1–39.9 g/day and women 0.1–19.9 g/day), high 
(men ≥40 g/day and women ≥20 g/day). iT-test; jMann–Whitney U test; kchi-square test.
Table 2 Odds ratios (95% confidence interval) for metabolic syndrome and single components of the metabolic syndrome as 
dependent variables and sUmod as independent variable (per standard deviation): results of logistic regression models.
Metabolic syndrome 
















Adjustment for sex and age
 0.58 (0.50–0.67)f 0.71 (0.59–0.86)f 0.69 (0.60–0.80)f 0.70 (0.60–0.81)f 0.69 (0.60–0.79)f 0.64 (0.54–0.75)f
Adjustment for sex, age and eGFR
 0.61 (0.53–0.70)f 0.71 (0.59–0.87)f 0.74 (0.64–0.86)f 0.76 (0.64–0.90)f 0.71 (0.62–0.81)f 0.67 (0.56–0.79)f
Adjustment for sex, age, eGFR, physical activity, smoking and alcohol consumption
 0.62 (0.53–0.72)f 0.73 (0.60–0.89)g 0.75 (0.64–0.87)f 0.78 (0.66–0.93)g 0.72 (0.62–0.82)f 0.67 (0.56–0.79)f
Adjustment for sex, age, eGFR, physical activity, smoking, alcohol consumption and hsCRP
 0.65 (0.56–0.76)f 0.82 (0.67–1.01) 0.75 (0.65–0.88)f 0.81 (0.68–0.97)h 0.74 (0.64–0.86)f 0.70 (0.59–0.83)f
fP < 0.001; gP < 0.01; hP < 0.05.
aDefined as ≥80 cm in women and ≥94 cm in men. bDefined as ≥1.7 mmol/l and/or intake of fibrates or nicotinic acid. cDefined as <1.0 mmol/l in men and 
<1.3 mmol/l in women and/or intake of fibrates or nicotinic acid. dDefined as ≥5.6 mmol/l and/or intake of anti-diabetic medication. eDefined as systolic 
blood pressure ≥130 mmHg and/or diastolic blood pressure ≥85 mmHg and/or use of antihypertensive medication, given that the participants were 
aware of being hypertensive.
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In addition to waist circumference, BMI and waist-
to-hip ratio were also inversely associated with sUmod 
after adjustment for sex and age (P < 0.001; Table 3). The 
association of sUmod with BMI remained significant in 
the multivariable regression models (P < 0.01), whereas its 
association with the waist-to-hip ratio lost significance 
after multivariable adjustment.
Analysis of further serum lipid parameters revealed 
an association between sUmod and increased total 
cholesterol, LDL and HDL cholesterol, and the ratio of 
total cholesterol to HDL cholesterol after adjustment for 
sex, age and eGFR. However, these associations did not 
remain significant in the fully adjusted model (Table 4). 
Thus, among the serum lipid parameters, only two major 
components of the metabolic syndrome, HDL cholesterol 
(β: 0.10 ± 0.03) and triglycerides (β: −0.10 ± 0.03), displayed 
a significant association with sUmod after multivariable 
adjustment.
Lack of an association of sUmod with incident 
metabolic syndrome in the longitudinal analysis
Baseline sUmod was not associated with new-onset 
metabolic syndrome or incidence of any component of the 
metabolic syndrome after the follow-up time of 6.5 ± 0.3 
years (Table 5). Furthermore, sUmod was not associated 
with changes of BMI or waist-to-hip ratio after adjustment 
for sex, age, eGFR and the respective baseline parameter 
(data not shown). After multivariable adjustment 
including sex, age, eGFR, physical activity, smoking, 
alcohol consumption, hsCRP, arterial hypertension, 
fasting glucose, BMI, the respective baseline parameter 
and intake of statins and fibrates in the follow-up 
examination, there was no association of sUmod with total 
cholesterol, LDL, HDL, the ratio of total cholesterol to HDL 
cholesterol and triglycerides in the follow-up examination 
(data not shown).
Discussion
The key finding of the current study is the strong and 
independent inverse relationship between sUmod and 
the metabolic syndrome in a large population-based 
elderly cohort. Low sUmod levels were associated with 
single components of the metabolic syndrome (elevated 
triglycerides, reduced HDL cholesterol, elevated fasting 
glucose and elevated blood pressure), indicating that 
sUmod is widely connected with metabolic alterations. To 
our knowledge, a detailed examination of the association 
of uromodulin with the metabolic syndrome has not been 
published before.
Table 3 Association estimates between sUmod and anthropometric outcome variables: β coefficient ± standard error from 
linear regression models are given per standard deviation sUmod (n = 1088).
BMI (continuous) Waist circumference (continuous) Waist-to-hip ratio (continuous)
Adjustment for sex and age
 −0.21 ± 0.03a −0.18 ± 0.02a −0.10 ± 0.02a
Adjustment for sex, age and eGFR
 −0.19 ± 0.03a −0.17 ± 0.03a −0.09 ± 0.02a
Adjustment for sex, age, eGFR, physical activity, smoking, alcohol consumption, hsCRP, arterial hypertension, fasting glucose 
 −0.08 ± 0.03b −0.08 ± 0.02b −0.04 ± 0.02
aP < 0.001; bP < 0.01.
Table 4 Association estimates between sUmod and parameters of lipid metabolism: β coefficient ± standard error from linear 
regression models are given per standard deviation sUmod (n = 1088).
Total cholesterol LDL cholesterol HDL cholesterol
Ratio total cholesterol to 
HDL cholesterol Triglycerides
Adjustment for sex and age
 0.12 ± 0.03a 0.10 ± 0.03b 0.21 ± 0.03a −0.12 ± 0.03a −0.18 ± 0.03a
Adjustment for sex, age and eGFR
 0.11 ± 0.03b 0.09 ± 0.03c 0.19 ± 0.03a −0.10 ± 0.03b −0.16 ± 0.03a
Adjustment for sex, age, eGFR, physical activity, smoking, alcohol consumption, hsCRP, arterial hypertension, fasting glucose, 
BMI, treatment with statins and fibrates
 0.06 ± 0.03 0.04 ± 0.03 0.10 ± 0.03a −0.54 ± 0.03 −0.10 ± 0.03a
aP < 0.001; bP < 0.01; cP < 0.05.
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In the urinary tract, uromodulin exerts 
immunomodulatory functions (9, 10). Whether 
immunomodulatory uromodulin properties also play 
a role in the circulation is not yet known. Nevertheless, 
uromodulin is capable of binding immunoglobulins 
and complement and to activate immune cells in 
experimental settings, indicating the presence of relevant 
systemic effects (22, 23, 24). Since obesity and metabolic 
syndrome are associated with low-grade inflammation, 
immunomodulatory sUmod properties might positively 
influence metabolism in this condition. This may serve as 
one explanation of an inverse connection of uromodulin 
and metabolic disturbances. In our cohort, sUmod was 
inversely associated with hsCRP (25). However, adjustment 
for hsCRP only moderately attenuated the association of 
sUmod with the metabolic syndrome and its components, 
indicating that chronic subclinical inflammation as assessed 
by hsCRP is not the only factor explaining the interplay of 
the metabolic syndrome and sUmod. Only the association 
of sUmod with elevated waist circumference was more 
strongly attenuated and lost significance after additional 
adjustment for hsCRP, possibly reflecting a stronger impact 
of chronic subclinical inflammation related to increased 
visceral adipose tissue on this association.
Despite the strong inverse associations in the cross-
sectional analysis, there was no evidence for an association 
between sUmod and the development of metabolic 
syndrome, nor any of its components. Thus, metabolic 
factors may negatively influence sUmod levels, indicating 
that the metabolic syndrome may impair tubular integrity 
and protein synthesis. Recently, Scheurlen et al. described 
an increase of sUmod following Roux-en-Y-gastric bypass in 
patients with severe obesity, indicating improved ‘kidney 
health’ or renal reserve after bariatric surgery, which was 
not detectable by traditional kidney function markers (26). 
We (25) and others (27) previously showed that sUmod was 
inversely associated with type 2 diabetes independently 
of the eGFR. Thus, sUmod possibly represents a tissue-
specific marker for early diabetic nephropathy that 
escapes GFR estimates due to diabetes-related glomerular 
hyperfiltration. The inverse association of sUmod with BMI 
and waist circumference independently of fasting glucose 
in the current study indicates that sUmod may also unravel 
other early kidney alterations related to hyperfiltration 
independently of hyperglycemia-related hyperfiltration. 
An inverse relation of sUmod with BMI was also described 
by Steubl et al. (12) and is possibly due to a relatively lower 
nephron mass in obesity, which is characteristically not 
detected by eGFR due to obesity-related hyperfiltration, 
but represents a risk factor for chronic kidney disease (2). 
However, in another cohort comprising 200 participants, 
of which 170 suffered from chronic kidney disease, sUmod 
was not associated with BMI (28). These discrepancies 
supposedly originate from differences in the study 
populations, since in overt preexisting chronic kidney 
disease, uromodulin values are substantially reduced as 
a sequelae of tubular atrophy, interstitial fibrosis and an 
overall loss of nephrons unrelated to metabolic alterations. 
The discrepancies between the studies emphasize the need 
to further elucidate the impact of sUmod on human health 
and disease in the general community.
The strong association of sUmod with HDL and 
triglycerides is a remarkable finding. In order to determine 
the independence of the correlation of sUmod with 
HDL and triglycerides from obesity and other metabolic 
traits, we performed a thorough adjustment for possible 
confounders. The associations still remained significant, 
indicating an intrinsic interaction of sUmod with HDL 
Table 5 Odds ratios (95% confidence interval) for incident metabolic syndrome and incident single components of the metabolic 
syndrome as dependent variables and sUmod as independent variable (per standard deviation): results of logistic regression 
models (n = 621). The numbers of participants with and without event are given in parentheses.
Metabolic syndrome 














pressuree (yes: n = 62; 
no: n = 126)
Adjustment for sex and age
 1.05 (0.79–1.39) 0.69 (0.45–1.07) 1.05 (0.74–1.50) 0.77 (0.40–1.50) 0.92 (0.71–1.19) 0.99 (0.70–1.40)
Adjustment for age, sex and eGFR
 1.13 (0.84–1.52) 0.69 (0.45–1.08) 1.03 (0.72–1.48) 0.79 (0.40–1.56) 0.96 (0.74–1.26) 0.99 (0.70–1.40)
Adjustment for sex, age, eGFR, physical activity, smoking, alcohol consumption and hsCRP
 1.18 (0.86–1.60) 0.75 (0.47–1.21) 1.03 (0.71–1.48) 0.68 (0.34–1.36) 1.00 (0.76–1.32) 1.07 (0.74–1.55)
aDefined as ≥80 cm in women and ≥94 cm in men. bDefined as ≥1.7 mmol/L and/or intake of fibrates. bDefined as ≥1.7 mmol/L and/or intake of fibrates. 
cDefined as <1.0 mmol/L in men and <1.3 mmol/l in women and/or intake of fibrates. dDefined as ≥5.6 mmol/L and/or intake of anti-diabetic medication. 
eDefined as systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥85 mmHg and/or use of antihypertensive medication, given that the 
participants were aware of being hypertensive. fNumber of participants with/without event.
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and triglycerides. In the urinary tract, uromodulin is 
able to bind various components including leukocytes, 
fimbriated bacteria and calcium phosphate nanocrystals 
(6). It is not yet clarified, whether sUmod also has similar 
properties in the circulation and can bind, modulate, 
neutralize or eliminate serum components as well. 
Intrinsic systemic effects of sUmod are very probable. 
For example, sUmod is inversely associated with incident 
cardiovascular events independently of the eGFR and well-
known traditional cardiovascular risk factors, indicating 
an intrinsic vasoprotective effect of the glycoprotein that 
has not yet been specified (29, 30). However, the weak or 
missing associations of sUmod with total cholesterol and 
LDL, and the lack of an association of sUmod with lipid 
levels in the longitudinal analysis argue against a broad 
implication of sUmod in lipid metabolism.
Study strengths and limitations
Strengths of our study are the population-based design 
with a large, well-characterized community-based 
cohort, and the follow-up time of 6.5 years. Unlike most 
previous studies using urinary uromodulin, we measured 
sUmod with a sensitive and robust ELISA. In contrast to 
uromodulin of urine origin, which forms various polymers 
with changing episodes and different antigenic sites (31), 
sUmod is a stable antigen lacking such important pre-
analytical disadvantages (13). To our knowledge, this is 
the first study elucidating the association of sUmod with 
the metabolic syndrome. However, only participants aged 
62–81 years were included, so that the relation of sUmod 
with metabolic disturbances remains to be confirmed in 
a younger population. Further, the incidence of some 
single components of the metabolic syndrome, namely 
elevated triglycerides and reduced HDL cholesterol was 
relatively low, limiting the power of the study in these 
longitudinal analyses.
Conclusions
We demonstrate an inverse association of prevalent 
metabolic syndrome with sUmod in elderly study 
participants from the general community. Further studies 
are required to assess whether a decrease of sUmod levels 
in metabolic syndrome, indicating tubular injury, reflects 
a reduced renal reserve due to a relatively lower nephron 
mass in this condition or whether obesity and other risk 
factors in concert with the metabolic syndrome influence 
uromodulin biosynthesis.
Supplementary data
This is linked to the online version of the paper at https://doi.org/10.1530/
EC-19-0352.
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